Bayer forms cancer-drug partnership with Loxo

(Reuters) - Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

Bayer forms cancer-drug partnership with Loxo

Alliance could see Loxo net up to $1.55bn in upfront and milestone payments

Fri 17 Nov 17 from Chemistry World

Bayer, Loxo to jointly develop TRK inhibitors

Cancer drug pact could be worth up to $1.5 billion

Tue 14 Nov 17 from CandEN

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

(Reuters) - Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, ...

Tue 14 Nov 17 from Reuters

Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal

(Reuters) - Loxo Oncology Inc will collaborate with Germany's Bayer AG to develop and commercialize two of its cancer therapies, the companies said on Tuesday, in deal that could bring the U.S. ...

Tue 14 Nov 17 from Reuters

  • Pages: 1

Bookmark

Bookmark and Share